Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Combined Modality Therapy for Stage III NSCLC
NCT01822496Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2013
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, crizotinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Nov 2013; status: terminated.
02
Drugs
erlotinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01822496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822496.